EUS-guided radiofrequency ablation for pancreatic insulinoma: experience in 2 tertiary centers.

Details

Serval ID
serval:BIB_C40F3E310F5D
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
EUS-guided radiofrequency ablation for pancreatic insulinoma: experience in 2 tertiary centers.
Journal
Gastrointestinal endoscopy
Author(s)
Marx M., Trosic-Ivanisevic T., Caillol F., Demartines N., Schoepfer A., Pesenti C., Ratone J.P., Robert M., Giovannini M., Godat S.
ISSN
1097-6779 (Electronic)
ISSN-L
0016-5107
Publication state
Published
Issued date
06/2022
Peer-reviewed
Oui
Volume
95
Number
6
Pages
1256-1263
Language
english
Notes
Publication types: Journal Article
Publication Status: ppublish
Abstract
Insulinoma is the most frequent functional neuroendocrine tumor of the pancreas, and preserving surgery is the treatment of choice. EUS-guided radiofrequency ablation (EUS-RFA) is a novel and promising technique that induces tissue necrosis of localized lesions. This article presents a preliminary clinical experience in treating pancreatic insulinomas <2 cm by EUS-RFA, focusing on safety and efficacy.
The clinical course of patients with pancreatic insulinoma treated by EUS-RFA at 2 tertiary referral centers was analyzed.
Between November 2017 and December 2020, 7 patients were included (6 women; mean age, 66 years). EUS-RFA was feasible in all patients with immediate hypoglycemia relief after only 1 single treatment session; 6 of 7 achieved complete response by cross-sectional imaging and remained asymptomatic (median follow-up, 21 months; range, 3-38). Three patients had minor adverse events. One elderly patient developed a large retrogastric collection 15 days after treatment and died 1 month after EUS-RFA.
Management of pancreatic neuroendocrine tumors <2 cm by EUS-RFA seems to be effective with an acceptable safety profile. However, further evidence focusing on long-term survival and recurrence is needed.
Keywords
Aged, Catheter Ablation/methods, Endosonography/methods, Female, Humans, Insulinoma/diagnostic imaging, Insulinoma/surgery, Pancreatic Neoplasms/diagnostic imaging, Pancreatic Neoplasms/etiology, Pancreatic Neoplasms/surgery, Radiofrequency Ablation/adverse effects
Pubmed
Create date
20/12/2021 13:52
Last modification date
28/05/2022 6:34
Usage data